Non-vascular Stents Market: as Boston Scientific commits approximately USD 14.5 billion to acquire Penumbra in one of interventional medicine's largest transactions in years, the deal's primary logic sits in neurovascular and peripheral vascular intervention, yet its scale signals how aggressively the largest device companies are now willing to spend to secure interventional platform breadth, a capital appetite that non-vascular stent specialists should read as a signal of what future consolidation in adjacent GI and biliary intervention categories could look like, not evidence that this specific transaction touches their own market directly.

The global non-vascular stents market size was USD 1.76 Billion in 2025 and is expected to register a revenue CAGR of 4.8% during the forecast period. Market revenue growth is driven by factors such as the documented rising global incidence of gastrointestinal malignancies requiring palliative biliary and esophageal decompression, self-expanding metal stent adoption displacing plastic alternatives at therapeutic endoscopy programmes, and endoscopic ultrasound-guided drainage technique expansion widening the addressable procedure base for non-vascular stent platforms. The first driving factor is the documented rising global incidence of gastrointestinal malignancies, which directly drives demand for palliative biliary and esophageal decompression procedures. Biliary stents account for a substantial share of total 2025 market revenue, reflecting biliary obstruction's position as the most common non-vascular stenting indication. The second driving factor is self-expanding metal stent adoption displacing plastic alternatives, as SEMS platforms demonstrate superior patency duration for malignant obstruction management at therapeutic endoscopy programmes. The third driving factor is endoscopic ultrasound-guided drainage technique expansion, which widens the addressable procedure base for non-vascular stent platforms beyond traditional ERCP-delivered indications. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single stent platform's integration into a combined endoscope-and-stent commercial relationship converts a standalone device purchase into a recurring, broader-portfolio account relationship, which lets the manufacturer capture a hospital or endoscopy centre's total non-vascular stenting spend across biliary, esophageal, and colonic indications through one established commercial channel rather than competing product by product. Because a hospital endoscopy programme's non-vascular stent purchasing increasingly follows its established endoscope equipment relationship, a manufacturer combining endoscope hardware and stent portfolio under one commercial platform captures a disproportionate share of that programme's total stenting spend across every indication the combined platform covers, so integrated platforms compound revenue capture across an entire procedure portfolio rather than a single device category. As a result, demand and revenue share are concentrating around manufacturers offering the broadest combined endoscope-and-stent commercial relationship, and the forecast tilts toward these integrated platforms rather than standalone stent specialists competing on device merits alone. For instance, in January 2024, Olympus completed its acquisition of Taewoong Medical for approximately USD 370 million, integrating the NITI-S family of self-expanding metal stents covering biliary, esophageal, duodenal, and colonic indications into the Olympus GI Endo Therapy portfolio and creating the first integrated endoscope and non-vascular SEMS commercial platform. These are some of the key factors driving revenue growth of the market.

Because stent migration and tumor or tissue ingrowth causing re-obstruction remain documented limitations even for the newest covered stent designs, physicians must weigh a stent's expected patency duration against the invasiveness of a repeat procedure when a stent fails, which continues to shape technique and product selection even as newer designs improve on older ones.

Expanding EU MDR post-market clinical follow-up requirements are a second constraint, since the EU Medical Device Regulation continues full enforcement for stent products including additional post-market clinical follow-up requirements for Class III non-vascular SEMS, requiring manufacturers to execute ongoing PMCF clinical data collection programmes as a condition of maintaining CE Mark certification validity.

Reimbursement variability for advanced stenting indications is a third constraint, since coverage for newer EUS-guided drainage applications varies meaningfully by country and payer, which creates inconsistent adoption even where clinical guidelines support expanded stent use.

These factors substantially limit non-vascular stents market growth over the forecast period.

The clearest driver of demand is the documented rising global incidence of gastrointestinal malignancies, which directly drives demand for palliative biliary and esophageal decompression procedures. A malignant GI obstruction that cannot be surgically resected still requires a way to restore luminal patency for the patient's remaining quality of life, so stent placement becomes a core palliative care intervention that tracks GI cancer incidence trends directly, independent of any single manufacturer's product cycle. Biliary stents account for a substantial share of total 2025 market revenue, and Boston Scientific's WallFlex family remains, by the company's own description, the most frequently implanted biliary metal stent worldwide, with the company launching a next-generation fully covered version in March 2024 designed to reduce migration risk and improve removal ease. The effect on the market is that baseline non-vascular stent demand tracks global GI cancer incidence trends closely, providing a stable demand floor beneath the market's platform-level competitive dynamics. These are some of the key factors driving revenue growth of the market.

The second driver is self-expanding metal stent adoption displacing plastic alternatives, as SEMS platforms demonstrate superior patency duration for malignant obstruction management at therapeutic endoscopy programmes relative to conventional plastic stents. A plastic biliary or esophageal stent typically requires more frequent replacement due to earlier occlusion than a metal stent, so a SEMS platform offering meaningfully longer patency directly reduces the number of repeat procedures a palliative care patient must undergo, a genuine quality-of-life consideration for patients with limited remaining treatment timelines. Cook Medical and Getinge signed a commercial distribution agreement for the Cook iCast covered stent system in the United States in March 2024, expanding the commercial footprint of the covered biliary stent through Getinge's distribution network alongside Cook Medical's existing direct sales channel. The effect on the market is that SEMS platforms continue capturing share from plastic stent alternatives across the broadest range of malignant obstruction indications. These are some of the key factors driving revenue growth of the market.

Boston Scientific's approximately USD 14.5 billion agreement to acquire Penumbra, announced in February 2026, is one of interventional medicine's largest transactions in years. Even where the deal's core logic sits outside GI stenting specifically, its scale signals the capital the largest device companies are now willing to commit to interventional platform breadth.

The third driver is endoscopic ultrasound-guided drainage technique expansion, which widens the addressable procedure base for non-vascular stent platforms beyond traditional ERCP-delivered indications into gallbladder and pancreatic pseudocyst drainage applications. EUS-guided drainage offers a less invasive alternative to surgical drainage for patients who are poor surgical candidates or where conventional ERCP-based cannulation has failed, so as stent platforms accumulate additional cleared EUS-guided indications, the category addresses a growing set of patients who previously had limited non-surgical treatment options. In February 2026, Boston Scientific announced a definitive agreement to acquire Penumbra for approximately USD 14.5 billion, a transaction primarily expanding Boston Scientific's neurovascular and peripheral interventional device portfolio, illustrating the scale of capital the largest device companies are now committing to interventional platform breadth broadly. The effect on the market is that EUS-guided applications represent the category's fastest-expanding clinical use case, even as broader interventional device consolidation activity like the Penumbra transaction signals how much capital is flowing into adjacent device categories. These are some of the key factors driving revenue growth of the market.

However, the non-vascular stents market faces severe adoption constraints from stent migration and re-obstruction rates that limit long-term patency, and expanding EU MDR post-market clinical follow-up requirements that raise the cost of maintaining CE Mark certification.

Because stent migration and tumor or tissue ingrowth causing re-obstruction remain documented limitations even for the newest covered stent designs, including Boston Scientific's next-generation WallFlex platform, physicians must weigh a stent's expected patency duration against the invasiveness of a repeat procedure when a stent fails, which continues to shape technique and product selection even as newer designs improve on older ones.

Expanding EU MDR post-market clinical follow-up requirements compound this, since the EU Medical Device Regulation continued full enforcement from June 2025 for stent products including additional post-market clinical follow-up requirements for Class III non-vascular SEMS, requiring manufacturers to execute ongoing PMCF clinical data collection programmes as a condition of maintaining CE Mark certification validity for biliary and esophageal SEMS products marketed in EU member state gastroenterology programmes.

Reimbursement variability for advanced stenting indications is the third constraint, since coverage for newer EUS-guided drainage applications varies meaningfully by country and payer, which creates inconsistent adoption even where clinical guidelines support expanded stent use.

These factors substantially limit non-vascular stents market growth over the forecast period.

Based on product type, the global non-vascular stents market is segmented into biliary, esophageal, colonic, duodenal and pancreatic, and tracheobronchial stents. Biliary stents hold the largest revenue share, because biliary obstruction from malignant and benign causes represents the single most common non-vascular stenting indication, which suits a market where the highest-volume clinical indication commands the largest revenue category. Esophageal stents remain established for malignant dysphagia palliation and benign stricture management, anchored by Boston Scientific's WallFlex and comparable covered SEMS designs. Duodenal and pancreatic stents are expected to register the fastest revenue growth rate in the global non-vascular stents market over the forecast period, driven by expanding EUS-guided pancreatic pseudocyst drainage applications.

Based on material, the global non-vascular stents market is segmented into self-expanding metal stents, plastic or polymer stents, and biodegradable stents. Self-expanding metal stents hold the largest revenue share, because they provide longer patency than plastic alternatives for malignant obstruction, which ties directly back to the SEMS displacement dynamic described in the market's primary demand driver. Biodegradable stents are expected to register the fastest revenue growth rate in the global non-vascular stents market over the forecast period, driven by their combination of temporary structural support for benign strictures with elimination of the removal procedure a permanent stent requires.

Malignant obstruction application is expected to account for the largest revenue share in the global non-vascular stents market during the forecast period

Based on application, the global non-vascular stents market is segmented into malignant obstruction, benign obstruction, and EUS-guided drainage. Malignant obstruction holds the largest revenue share, reflecting the volume of palliative stenting cases across biliary and esophageal cancer indications. EUS-guided drainage is expected to register the fastest revenue growth rate in the global non-vascular stents market over the forecast period, driven by expanding clinical evidence supporting this pathway as an alternative to conventional ERCP for gallbladder and pancreatic pseudocyst drainage.

Based on regional analysis, the non-vascular stents market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of GI cancer treatment centres and interventional endoscopy programmes sustains the highest stenting procedure volume globally, and because Boston Scientific, Olympus, and Cook Medical all maintain their primary commercial presence in the US market. Boston Scientific's WallFlex platform's position as the most frequently implanted biliary metal stent worldwide specifically reinforces the country's role as this market's largest single national market. The scale of US GI cancer incidence anchors a domestic stent market large enough to sustain multiple competing platforms simultaneously.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. The EU MDR's continued full enforcement, including expanded post-market clinical follow-up requirements from June 2025, shapes ongoing manufacturer compliance investment across the region. The result is steady rather than rapid growth, shaped more by regulatory compliance cost than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. South Korea and Japan represent two of the most established national markets within the region, reflecting Taewoong Medical's Korean manufacturing base and Olympus' Japanese corporate headquarters. China's rapidly expanding GI cancer treatment infrastructure leaves considerably more room for growth than in the already stent-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital networks driving early adoption of advanced stent platforms among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the nitinol alloy and precision delivery system components that Latin American device distributors depend on, an effect expected to run through 2026 and slow non-vascular stent adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding oncology treatment infrastructure and the UAE's regional distribution hubs represent the primary investment centres for non-vascular stent adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the interventional endoscopy infrastructure needed to support advanced stent platforms at scale.